Geron(US:GERN) Prnewswire·2025-03-21 13:25Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the May 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Geron [2]. - The complaint alleges that Geron and its executives made false and misleading statements regarding the company's drug Rytelo, downplaying risks associated with its monitoring requirements and competition [4]. - Investors who suffered losses exceeding $100,000 in Geron between February 28, 2024, and February 25, 2025, are encouraged to contact the firm for legal options [1]. Group 2: Financial Performance and Stock Impact - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal 2024, revealing that Rytelo's growth had flattened due to seasonality, competition, and lack of awareness [5]. - Following the announcement, Geron's stock price plummeted from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [6].